Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended interval dosing of natalizumab in multiple sclerosis.
Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM. Zhovtis Ryerson L, et al. Among authors: green r. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25. J Neurol Neurosurg Psychiatry. 2016. PMID: 26917698
Vitamin D in African Americans with multiple sclerosis.
Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, Mowry EM, Miller JW, Hauser SL, Green AJ. Gelfand JM, et al. Among authors: green r, green aj. Neurology. 2011 May 24;76(21):1824-30. doi: 10.1212/WNL.0b013e31821cccf5. Neurology. 2011. PMID: 21606454 Free PMC article.
Serum cobalamin deficiency is uncommon in multiple sclerosis.
Goodkin DE, Jacobsen DW, Galvez N, Daughtry M, Secic M, Green R. Goodkin DE, et al. Among authors: green r. Arch Neurol. 1994 Nov;51(11):1110-4. doi: 10.1001/archneur.1994.00540230048011. Arch Neurol. 1994. PMID: 7980105
Alzheimer disease biomarkers are associated with body mass index.
Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative. Vidoni ED, et al. Neurology. 2011 Nov 22;77(21):1913-20. doi: 10.1212/WNL.0b013e318238eec1. Neurology. 2011. PMID: 22105948 Free PMC article.
Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.
Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogaeva E, Barmada MM, Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Martin ER, Haines JL, Mayeux RP, Farrer LA, Schellenberg GD, Pericak-Vance MA; Alzheimer Disease Genetics Consortium; Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barnes LL, Beach TG, Becker JT, Beekly D, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Dick M, Dickson DW, Duara R, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT… See abstract for full author list ➔ Naj AC, et al. Among authors: green rc. JAMA Neurol. 2014 Nov;71(11):1394-404. doi: 10.1001/jamaneurol.2014.1491. JAMA Neurol. 2014. PMID: 25199842 Free PMC article.
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
Young CB, Winer JR, Younes K, Cody KA, Betthauser TJ, Johnson SC, Schultz A, Sperling RA, Greicius MD, Cobos I, Poston KL, Mormino EC; Alzheimer’s Disease Neuroimaging Initiative and the Harvard Aging Brain Study. Young CB, et al. JAMA Neurol. 2022 Jun 1;79(6):592-603. doi: 10.1001/jamaneurol.2022.0676. JAMA Neurol. 2022. PMID: 35435938 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Treatment trial of oxiracetam in Alzheimer's disease.
Green RC, Goldstein FC, Auchus AP, Presley R, Clark WS, Van Tuyl L, Green J, Hersch SM, Karp HR. Green RC, et al. Among authors: green j. Arch Neurol. 1992 Nov;49(11):1135-6. doi: 10.1001/archneur.1992.00530350049018. Arch Neurol. 1992. PMID: 1444879 Clinical Trial.
5,200 results